Lagoda Investment Management, its general partner and Fatima Dickey shifted their VOLITIONRX LTD ownership reporting from passive Schedule 13G to activist Schedule 13D while reporting a 7.4% stake, or 1,652,005 shares. The change matters because they now cite a purpose connected with influencing control and recommend lower executive compensation and operating expenses.
Key Highlights
- Fatima Dickey’s letter supported VOLITIONRX LTD management and the long-term potential of its intellectual property and products.
- The reported position includes 1,480,950 common shares and warrants exercisable for 171,055 additional shares.
- The securities were acquired for approximately $10,970,373, excluding brokerage commissions.
VOLITIONRX LTD (AMEX: VNRX) now has an activist ownership position from Lagoda Investment Management, L.P. Lagoda Investment Management, LLC and Fatima Dickey, who report beneficial ownership of 7.4%, or 1,652,005 shares (1.65 million). The group previously reported the position under Schedule 13G and has shifted to Schedule 13D.
The Reported Position
The common stock has a Par Value of $0.001 per share. The three reporting persons may each be deemed to beneficially own the aggregate position. Lagoda Investment Management, L.P. manages the accounts holding the securities and has voting and dispositive power over the common stock and other securities in those accounts. Lagoda Investment Management, LLC is the general partner of the investment manager. Fatima Dickey, as the LLC’s sole member, may be deemed to share that voting and dispositive power. The securities were acquired in the ordinary course of the investment manager’s Business for investment purposes. Approximately $10,970,373 was paid for them, excluding brokerage commissions.
From Passive To Activist
The group most recently reported beneficial ownership under Schedule 13G in an amendment dated August 14, 2026. The current Schedule 13D reflects a stated purpose that may relate to changing or influencing control of VOLITIONRX LTD. Fatima Dickey delivered a letter to the board on or about August 17, 2026. The letter expressed support for VOLITIONRX LTD management and for the long-term potential of the company’s intellectual property and products. The reporting persons currently do not intend to seek representation on the board.
Securities And Future Moves
A second group of warrants covers 125,000 shares at an exercise price of $1.55 per share and expires in June 2031. Each Warrant includes a 4.99% beneficial ownership limitation. The holder may elect to change that limit, subject to a maximum of 9.99% and 61 days’ prior notice to VOLITIONRX LTD for an increase. The reporting persons reserve the right, subject to applicable law, to acquire additional securities, dispose of some or all securities held in the accounts, or develop other purposes, plans or proposals concerning VOLITIONRX LTD or its securities. The group also states that it may review its position, change its purpose or formulate plans concerning the company’s securities.





Please wait processing your request...